Acotec Scientific Holdings Ltd (HKG: 6669) has announced that its Vericor-S2 coronary microcatheter has received registration approval from the National Medical Products Administration (NMPA). The product is designed for use in percutaneous coronary interventions, specifically for guiding guidewires through narrow vessel lesions and providing a channel for saline or contrast media.
Innovative Design and Benefits
The Vericor-S2 features an innovative hybrid weaving process that significantly enhances the tensile strength of the microcatheter while reducing its elongation. This design improves the catheter’s resistance to breakage, thereby lowering the risk of adverse events. Additionally, leveraging Acotec’s material technology and hybrid weaving process, the Vericor-S2 coronary microcatheter offers several times the pressure resistance of conventional woven microcatheters. It can withstand a maximum injection pressure of up to 600psi, ensuring safety during clinical use.
Future Outlook
With this NMPA approval, Acotec Scientific is poised to expand its presence in the coronary intervention market. The Vericor-S2 microcatheter’s innovative design and enhanced performance position it as a valuable tool for improving procedural outcomes and patient safety in cardiovascular interventions.-Fineline Info & Tech
Leave a Reply